Loading
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Latest filing published 07 Aug 2026 for Royalty Pharma plc. Read the official filing
Filing timeline
BuySalePablo G. Legorreta
Insider track record
Disclosed buys
6
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-10.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Pablo G. Legorreta: trading record in brief
Pablo G. Legorreta, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Royalty Pharma plc, Prokidney Corp. and Epizyme, Inc. Between 16 June 2020 and 5 August 2026, the trades on record add up to 20 filings.
Every open-market trade on record is a purchase: 6 purchases worth €95.8M, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 5 share grants.
In size, the median ticket on the buying side is €4.7M. Across 6 purchases, this insider has always bought alone, with no colleague buying within 30 days.
The latest filing, published on 7 August 2026, reports a share grant in Royalty Pharma plc. The clock since the last published purchase (14 June 2024) now reads 856 days. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Pablo G. Legorreta
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations20 total
65,216 shares0Class A Ordinary SharesSEC:0001507678-26-000006:0
157,828 shares0Class A Ordinary SharesSEC:0001507678-26-000002:0
36,559 shares0Class A Ordinary SharesSEC:0001507678-25-000010:0
21,901 shares0Class A Ordinary SharesSEC:0001802768-25-000105:0
3,823,996 shares0Class A Ordinary SharesSEC:0000950170-25-082342:0
530,348 shares0Class A Ordinary SharesSEC:0001802768-25-000063:0
288,352 shares0Class A Ordinary SharesSEC:0001802768-25-000039:0
532,535 shares0Class A Ordinary SharesSEC:0000950170-25-015495:0
22,617,909 shares@ US$2.42100.0% of flowClass A Ordinary SharesSEC:0000950170-24-073633:0
Canonical exit: 11 Sept 2024 (T+90)
748,952 shares0Class A Ordinary SharesSEC:0000950170-24-011711:0
292,190.49 shares0Class A ordinary sharesSEC:0000950103-23-016404:0
5,289,055 shares0Class A Ordinary SharesSEC:0001209191-23-054044:0
130,000 shares@ US$29.513624.5% of flowClass A ordinary sharesSEC:0001209191-23-040024:0
Canonical exit: 26 Sept 2023 (T+90)
45,000 shares@ US$32.99889.6% of flowClass A ordinary sharesSEC:0001209191-23-036624:0
Canonical exit: 10 Sept 2023 (T+90)
150,000 shares@ US$32.249631.3% of flowClass A ordinary sharesSEC:0000950103-23-007785:0
Canonical exit: 22 Aug 2023 (T+90)
160,388 shares@ US$33.566934.5% of flowClass A ordinary sharesSEC:0000950103-23-007427:0
Canonical exit: 14 Aug 2023 (T+90)
31,933,334 sharesCommon Stock, par value $0.0001SEC:0000899243-22-028860:0
493,750 shares0Class A Ordinary SharesSEC:0000950103-22-006475:0
22,666,667 shares@ US$1.50100.0% of flowCommon StockSEC:0000899243-22-003857:0
Canonical exit: 1 May 2022 (T+90)
1,040,410 shares0Class A Ordinary SharesSEC:0000950103-21-007075:0
20 of 20 declarations
